December 2006
Worldwide Biotech;Dec2006, Vol. 18 Issue 12, p6
Trade Publication
The article reports on the failure of CellCept in treating myasthenia gravis to meet both primary and secondary endpoints in its phase III clinical trial according to Aspreva Pharmaceuticals Corp. The trial was designed to evaluate the efficacy and safety of mycophenolate mofetil in maintaining or improving symptom control with reduced doses of corticosteroids in patients with myasthenia gravis. CellCept is the leading immunosuppressant or anti-rejection drug of Roche used in combination with other immunosupressive drugs.


Related Articles

  • 2nd Phase III CellCept Failure Sends Aspreva Shares Down. Morrison, Trista // BioWorld Today;6/28/2007, Vol. 18 Issue 125, p1 

    The article reports on a decrease in the shares of Aspreva Pharmaceuticals Corp. after it revealed that the induction portion of a Phase III clinical trial of CellCept failed. It states that the trial has failed to establish the superiority of CellCept to intravenous cyclophosphamide (IVC), a...

  • Long-Term Colectomy Rate After Intensive Intravenous Corticosteroid Therapy for Ulcerative Colitis Prior to the Immunosuppressive Treatment Era. Gustavsson, Anders; Halfvarson, Jonas; Magnuson, Anders; Sandberg-Gertzén, Hanna; Tysk, Curt; Järnerot, Gunnar // American Journal of Gastroenterology;Nov2007, Vol. 102 Issue 11, p2513 

    OBJECTIVES: Corticosteroids are a cornerstone in the treatment of a severe attack of ulcerative colitis (UC). The long-term prognosis in this patient group is not well described. We studied the long-term colectomy and relapse rates in patients given intensive intravenous corticosteroid treatment...

  • The natural course of myasthenia gravis. Fonseca, V.; Havard, C.W.H. // BMJ: British Medical Journal (International Edition);6/2/90, Vol. 300 Issue 6737, p1409 

    Examines the use of thymectomy, corticosteroid and immunosuppressive agents in the treatment of myasthenia gravis in Great Britain. Reduction of morbidity; Requirement of long duration of treatment; Beneficial effects of the drugs.

  • Immune Globulin Intravenous: Myasthenia Gravis (Acute Exacerbation). Generali, Joyce A.; Cada, Dennis J. // Hospital Pharmacy;Oct2015, Vol. 50 Issue 9, p773 

    This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide...

  • Management of acute severe ulcerative colitis. Gert Van Assche // Gut;Jan2011, Vol. 60 Issue 1, p130 

    Acute severe ulcerative colitis is a potentially lethal condition that requires a pro-active approach with either effective medical treatment or timely colectomy. Although intravenous corticosteroids remain the first line treatment, in patients not responding after 3–5 days rescue...

  • Intraocular Implants for the Treatment of Autoimmune Uveitis. Lee, Darren J. // Journal of Functional Biomaterials;2015, Vol. 6 Issue 3, p650 

    Uveitis is the third leading cause of blindness in developed countries. Currently, the most widely used treatment of non-infectious uveitis is corticosteroids. Posterior uveitis and macular edema can be treated with intraocular injection of corticosteroids, however, this is problematic in...

  • Immunosuirnressant drugs for mvasthenia aravis. Hart, I. K.; Sharshar, T.; Sathasivam, S. // Journal of Neurology, Neurosurgery & Psychiatry;Jan2009, Vol. 80 Issue 1, p5 

    Along with corticosteroids, immunosuppressant drugs are mainstays of disease-modifying therapy for myasthenia gravis (MG). However, their efficacies and optimum use are unclear. We identified seven randomised controlled trials (ACT) of immunosuppressants in generalised MG that qualified for...

  • Clinical Trial Design in Studies of Corticosteroids for Bacterial Infections. Weitzman, Stephen; Berger, Stephen // Annals of Internal Medicine;Jul74, Vol. 81 Issue 1, p36 

    Examines several studies on corticosteroid therapy and its adherence to the standards of clinical trial design. Discussion on the methodologic standards of a proper experimental design and interpretation; Observations on the corticosteroid administration details of the studies; Analysis of the...

  • Early intervention with low-dose inhaled corticosteroid (ICS) therapy is beneficial in patients with mild persistent asthma.  // Drugs & Therapy Perspectives;Apr2008, Vol. 24 Issue 4, p9 

    Treatment of mild asthma with low-dose inhaled corticosteroids (ICSs) improves control of the disease and prevents disease exacerbation. Early treatment with ICSs appears to diminish, but not completely prevent, the decline in airway function in patients with asthma, although the positive...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics